共 31 条
[1]
Harrison C(2012)JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis N Engl J Med 366 787-798
[2]
Kiladjian JJ(2012)A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis N Engl J Med 366 799-807
[3]
Al-Ali HK(2013)Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood 122 3843-3844
[4]
Verstovsek S(2014)Hepatitis B virus reactivation associated with ruxolitinib Ann Hematol 93 1075-1076
[5]
Mesa RA(2013)Progressive multifocal leukoencephalopathy associated with ruxolitinib N Engl J Med 369 197-198
[6]
Gotlib J(2013)Bilateral toxoplasmosis retinitis associated with ruxolitinib N Engl J Med 369 681-683
[7]
Heine A(2013)An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor Chest 143 1478-1479
[8]
Brossart P(2013)JAKs and STATs in immunity, immunodeficiency, and cancer N Engl J Med 368 161-170
[9]
Wolf D(2013)The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo Blood 122 1192-1202
[10]
Shen CH(2015)JAK inhibition impairs NK cell function in myeloproliferative neoplasms Cancer Res 75 2187-2199